LEVAQUIN by Johnson & Johnson is [see microbiology(12. Approved for moderate, severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section, nosocomial pneumonia due to methicillinsusceptible staphylococcus aureus and 36 more indications. First approved in 1996.
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
LEVAQUIN (levofloxacin) is a fluoroquinolone antibiotic approved in 1996 for moderate to severe infections caused by susceptible bacteria. It treats community-acquired pneumonia, nosocomial pneumonia, acute bacterial sinusitis, chronic bacterial prostatitis, and complicated/uncomplicated skin and urinary tract infections. The drug works by inhibiting bacterial DNA gyrase and topoisomerase IV, disrupting bacterial DNA replication.
As a mature fluoroquinolone approaching loss of exclusivity, LEVAQUIN brand teams are likely focused on lifecycle management and defending market share against generic and newer competitive alternatives.
[see Microbiology(12.4)]. 12.3 Pharmacokinetics The mean ±SD pharmacokinetic parameters of levofloxacin determined under single and steady-state conditions following oral tablet, oral solution, or intravenous (IV) doses of levofloxacin are summarized in Table 8. Table 8: Mean ±SD Levofloxacin PK…
Worked on LEVAQUIN at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
LEVAQUIN roles are declining as the product approaches loss of exclusivity; opportunities exist primarily in managed care, specialty distribution, and defensive marketing against generics. Career growth on this brand is limited; professionals should expect transition planning, portfolio consolidation, or movement to growth-stage products.